Skip to main content

Research Repository

Advanced Search

Clostridioides difficile: innovations in target discovery and potential for therapeutic success

Monaghan, Tanya M.; Seekatz, Anna M.; Mullish, Benjamin H.; Moore-Gillon, Claudia E.R.; Dawson, Lisa; Ahmed, Ammar; Kao, Dina; Chan, Weng C.

Clostridioides difficile: innovations in target discovery and potential for therapeutic success Thumbnail


Authors

TANYA MONAGHAN Tanya.Monaghan@nottingham.ac.uk
Clinical Associate Professor in Luminal Gastroenterology

Anna M. Seekatz

Benjamin H. Mullish

Claudia E.R. Moore-Gillon

Lisa Dawson

Ammar Ahmed

Dina Kao



Abstract

Introduction: Clostridioides difficile infection (CDI) remains a worldwide clinical problem. Increased incidence of primary infection, occurrence of hypertoxigenic ribotypes, and more frequent occurrence of drug resistant, recurrent, and non-hospital CDI, emphasizes the urgent unmet need of discovering new therapeutic targets. Areas covered: We searched PubMed and Web of Science databases for articles identifying novel therapeutic targets or treatments for C. difficile from 2001 to 2021. We present an updated review on current preclinical efforts on designing inhibitory compounds against these drug targets and indicate how these could become the focus of future therapeutic approaches. We also evaluate the increasing exploitability of gut microbial-derived metabolites and host-derived therapeutics targeting VEGF-A, immune targets and pathways, ion transporters, and microRNAs as anti-C. difficile therapeutics, which have yet to reach clinical trials. Our review also highlights the therapeutic potential of re-purposing currently available agents. We conclude by considering translational hurdles and possible strategies to mitigate these problems. Expert opinion: Considerable progress has been made in the development of new anti-CDI drug candidates. Nevertheless, a greater comprehension of CDI pathogenesis and host-microbe interactions is beginning to uncover potential novel therapeutic targets, which can be exploited to plug gaps in the CDI drug discovery pipeline.

Citation

Monaghan, T. M., Seekatz, A. M., Mullish, B. H., Moore-Gillon, C. E., Dawson, L., Ahmed, A., …Chan, W. C. (2021). Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opinion on Therapeutic Targets, 25(11), 949-963. https://doi.org/10.1080/14728222.2021.2008907

Journal Article Type Article
Acceptance Date Nov 17, 2021
Online Publication Date Dec 2, 2021
Publication Date Dec 2, 2021
Deposit Date Nov 19, 2021
Publicly Available Date Dec 3, 2022
Journal Expert Opinion on Therapeutic Targets
Print ISSN 1472-8222
Electronic ISSN 1744-7631
Publisher Informa UK Limited
Peer Reviewed Peer Reviewed
Volume 25
Issue 11
Pages 949-963
DOI https://doi.org/10.1080/14728222.2021.2008907
Keywords Clinical Biochemistry; Drug Discovery; Pharmacology; Molecular Medicine
Public URL https://nottingham-repository.worktribe.com/output/6737791
Publisher URL https://www.tandfonline.com/doi/full/10.1080/14728222.2021.2008907

Files




You might also like



Downloadable Citations